Please use this identifier to cite or link to this item:
Title: Long-term Inhaled Nitric Oxide Plus Phosphodiesterase 5 Inhibitors for Severe Pulmonary Hypertension
Authors: Pérez-Peñate, Gregorio Miguel 
Juliá-Serdà, Gabriel
Ojeda-Betancort, Nazario
García-Quintana, Antonio
Pulido-Duque, Juan
Rodríguez Pérez, Aurelio Eduardo 
Cabrera-Navarro, Pedro 
Gómez-Sánchez, Miguel Angel
UNESCO Clasification: 32 Ciencias médicas
3205 Medicina interna
Keywords: Pulmonary hypertension
Nitric oxide
Phosphodiesterase 5 Inhibitors
Cyclic GMP
Issue Date: 2008
Journal: Journal of Heart and Lung Transplantation 
Abstract: Background: Inhaled nitric oxide (iNO) is a potent pulmonary vasodilator, but therapeutic experience in patients with severe pulmonary hypertension is scarce. Methods: Eleven patients with severe pulmonary hypertension, 6 due to pulmonary arterial hypertension and 4 due to chronic thromboembolic disease, were selected for iNO therapy. A phosphodiesterase type 5 inhibitor (PDE5i) was added in cases of clinical worsening. In this study we evaluate the clinical effectiveness and safety of long-term treatment with iNO either alone or combined with a PDE5i. Results: After 1 month of iNO administration, improvements were observed in World Health Organization functional class, Borg scale (p = 0.003), brain natriuretic peptide levels (p = 0.002) and 6-minute walk test (p = 0.003). After 6 months of treatment, 7 patients had clinical deterioration that was reversed upon adding a PDE5i. One of these patients died in Month 8 and another underwent pulmonary transplantation in Month 9. The clinical condition of the remaining 9 patients was unchanged after 1 year. A second right catheterization showed improvement in mean pulmonary arterial pressure (66 +/- 15 mm Hg to 56 +/- 18 mm Hg; p = 0.01), pulmonary vascular resistance (1,234 +/- 380 dyn/s/cm(5) to 911 +/- 410 dyn/s/cm(5); p = 0.008) and cardiac index (2.0 +/- 0.4 liters/min/m(2) to 2.5 +/- 0.4 liters/min/m(2); p = 0.04). There was no significant increase in methemoglobin, no worsening of pulmonary function and no sudden withdrawal syndrome. Conclusions: We suggest that iNO therapy alone or in combination with a PDE5i could be a therapeutic alternative for severe pulmonary hypertension.
ISSN: 1053-2498
DOI: 10.1016/j.healun.2008.08.007
Source: Journal of Heart and Lung Transplantation[ISSN 1053-2498],v. 27(12), p. 1326-1332 (Octubre 2008)
Appears in Collections:Artículos
Show full item record


checked on Jun 26, 2022

Page view(s)

checked on May 28, 2022

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.